Himalaya Nutravedics — 360° view

Himalaya Nutravedics, a company in the Pharmaceuticals industry, reported revenue of ₹27 crore and net profit of ₹4.44 crore for the September 2026 quarter.

Himalaya Nutravedics (BSE: HNIL) closed at ₹170.00 on 20 Nov 2026. Its market capitalisation is ₹150 crore and it trades at 17.9 times earnings.

Share price
₹170.00 (20 Nov 2026)
Market cap
₹150 Cr (20 Nov 2026)
P/E
17.87 (20 Nov 2026)
Revenue
₹27 Cr (September 2026 quarter)
Net profit
₹4 Cr (September 2026 quarter)
ROCE
52.2% (FY26)
ROE
63.9% (FY26)
Book value
₹53.7 (FY26)
Dividend yield
0.00% (FY26)
52-week high / low
₹188.95 / ₹109.95 (20 Nov 2026)
Sector
Healthcare
Industry
Pharmaceuticals
Symbol
BSE: HNIL

Incorporated in June 2022, Himalaya Nutravedics India Limited is engaged in the manufacturing, marketing, and distribution of Ayurvedic and nutraceutical formulations.

Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.